“INSIDE INNOVATION” COLUMN
Irvine is the center of the universe for patients with weak heart valves.
To help those patients, two local companies – Edwards Lifesciences and CoreValve – have developed techniques for implanting aortic valves without major surgery.
The companies are competing to win the favor of regulators and then of doctors, first in Europe and then the United States.
The beneficiaries will be about 120,000 patients a year worldwide who need new aortic valves, typically because of calcium buildup, but are too frail or sick for major heart surgery.
Both companies’ devices use a catheter to replace a failing valve with one made of animal tissue.
Neither company has won approval to sell its latest products in the United States. So far the battlefields are in Europe. …
(READ MORE)
Reader comments: We want this to be a place where people discuss and debate ideas that foster stronger communities. We expect people to differ -- judgment and opinion are subjective -- and we encourage free speech and the exchange of ideas. But you are participating in a community that is intended for all of our users and we prohibit profanity, vulgarity, racial, sexual and homophobic remarks, threats, harassment and personal attacks. Here's the full User Agreement. Thank you for making this a safe place worth preserving and sharing. Share this: The icons below make it easy to share this post with others. First icon e-mails a link.
Posted in: Cross-pollination • Government regulation • New products • "Inside Innovation" columns • Breakthroughs • Clinical trials • CoreValve • Edwards Lifesciences • Incremental innovation • Intellectual property • Medical devices |
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
